Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study.
about
Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activityDown titration and discontinuation strategies of tumor necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activityCurrent concepts in the management of rheumatoid arthritisBiologicals in rheumatoid arthritis: current and futureSustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritisEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateStopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritisA New-Age for Biologic Therapies: Long-Term Drug-Free Therapy with BiP?Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS studyCost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management.Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study.Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trialCorrelation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study.Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review.[Rheumatoid arthritis].Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessoA multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remissionThe first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis.Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry.Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study.Biologic discontinuation studies: a systematic review of methodsCombination with methotrexate and cyclophosphamide attenuated maturation of dendritic cells: inducing Treg skewing and Th17 suppression in vivo.Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2.Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis.Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational studyWhen to initiate and discontinue biologic treatments for rheumatoid arthritis?Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission.Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence.German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.Tailoring anti-TNF therapy in IBD: drug levels and disease activity.Emerging immunotherapies for rheumatoid arthritis.Biologics in rheumatoid arthritis: where are we going?Optimizing the expediency of TNFi in rheumatoid arthritis: offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase.
P2860
Q24193435-9903D82A-721D-4E97-9478-12BA0252E194Q24198056-3CC5C0B0-79B4-496D-A02A-BBB279D26C19Q26765124-97597043-A17B-4216-BA04-1CB6A72306F0Q26780316-956474C5-C61D-421B-999F-8E43ECDEB80AQ26800154-752A7F8C-57D7-40B1-B8F5-EC3DD989C369Q26852081-961695B2-45ED-4408-816D-BED93F9545D0Q26859134-F56B3A01-3DD5-4DEB-AC94-05EE7C992EE9Q28071738-75B6115B-CA76-4EEE-84FA-5F6B5C32D202Q28730158-A77B0A31-9573-4ED9-8850-0E717A962884Q30249836-89A23845-D532-4C01-83BC-024D865C0A58Q30874158-59D6C570-98E1-4847-9C98-13D161491F4CQ33590773-D90F244A-75AD-4CC4-A582-32CD44C0EE0AQ33717053-59FB9A6A-423A-48E8-8590-31D7F71818BAQ34420269-06F83A76-EA2D-4542-9D24-78E8C14482BEQ35048301-8347D36E-E96F-467C-891E-64643DF0373FQ35214632-C97B3CD7-157B-4FEA-91B7-990C84BA8CF4Q35351313-61C4B5F1-E305-407E-BFF7-BB651D8F9FB3Q35907845-DD66BB70-B533-4D32-B3FA-0F544A748EE6Q36151778-CC866696-AEC7-4705-A519-E62E890C76B4Q36241682-668A8F70-6F4A-4857-81E4-1E4F2169684EQ36334999-2B2A87E7-1C9F-428C-BF1C-76BC20297558Q36473075-779C42B5-31AA-4BDD-96D9-85AEB0C972F9Q36475622-67DD166F-425F-461A-B6B6-C65554D85E24Q36475642-4D2A6584-4409-4E15-AF81-31B34FCAA914Q36573569-2A52E37C-DF5B-42FF-A567-5CF290CD052BQ36603276-ED58DA9A-B64E-4A1D-AB14-1394441151FAQ36812580-598991CC-4812-4B61-983B-7078DBAE26F4Q37249844-646F48F0-6A2E-4964-B91D-5251FD9E632DQ37465472-B184062D-6004-421E-8853-82C612C43464Q37567461-4931AAF2-90C9-49AC-862F-C5F301D75A35Q37690027-360F933C-C32D-4553-A36C-429EB1672F48Q37831972-4766322F-44AD-43E3-B524-445B6B3607D0Q37889842-F5DBECCA-F791-4688-9F90-27283948833FQ37894016-38B67CD1-CBD1-4689-8118-571A9882EC07Q37907921-602D258E-6DEA-43E9-A132-71EA11C3FCAAQ38128726-860AACFB-F8FB-4C5D-B14A-6C42AAE62F56Q38176154-2B2249C9-03F9-4EB7-BFAD-A63A2587C5BEQ38188862-77AAC40C-8E9F-41C9-8207-80D86944F75AQ38238799-572DE5AE-0209-4D60-8F72-425BBA780917Q38264653-0474E688-6112-4949-9A47-FCEDC1681EAD
P2860
Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Discontinuation of infliximab ...... tion by Remicade in RA) study.
@ast
Discontinuation of infliximab ...... tion by Remicade in RA) study.
@en
Discontinuation of infliximab ...... with rheumatoid arthritis: RRR
@nl
type
label
Discontinuation of infliximab ...... tion by Remicade in RA) study.
@ast
Discontinuation of infliximab ...... tion by Remicade in RA) study.
@en
Discontinuation of infliximab ...... with rheumatoid arthritis: RRR
@nl
prefLabel
Discontinuation of infliximab ...... tion by Remicade in RA) study.
@ast
Discontinuation of infliximab ...... tion by Remicade in RA) study.
@en
Discontinuation of infliximab ...... with rheumatoid arthritis: RRR
@nl
P2093
P2860
P356
P1476
Discontinuation of infliximab ...... tion by Remicade in RA) study.
@en
P2093
N Miyasaka
RRR study investigators
T Takeuchi
P2860
P304
P356
10.1136/ARD.2009.121491
P407
P50
P577
2010-04-01T00:00:00Z